HRP20140156T1 - Acetamidi supstituirani s n-(hetero)aril,2-(hetero)aril, koji se upotrebljavaju kao wnt-signalni modulatori - Google Patents
Acetamidi supstituirani s n-(hetero)aril,2-(hetero)aril, koji se upotrebljavaju kao wnt-signalni modulatori Download PDFInfo
- Publication number
- HRP20140156T1 HRP20140156T1 HRP20140156AT HRP20140156T HRP20140156T1 HR P20140156 T1 HRP20140156 T1 HR P20140156T1 HR P20140156A T HRP20140156A T HR P20140156AT HR P20140156 T HRP20140156 T HR P20140156T HR P20140156 T1 HRP20140156 T1 HR P20140156T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- pharmaceutically acceptable
- acceptable salt
- compound
- compound according
- Prior art date
Links
- 230000011664 signaling Effects 0.000 title claims 5
- 150000003869 acetamides Chemical class 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 25
- 150000003839 salts Chemical class 0.000 claims 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 208000035475 disorder Diseases 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000004193 piperazinyl group Chemical group 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- -1 pyranisyl Chemical group 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 241001481760 Erethizon dorsatum Species 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- XXYGTCZJJLTAGH-UHFFFAOYSA-N LGK974 Chemical compound C1=NC(C)=CC(C=2C(=CC(CC(=O)NC=3N=CC(=CC=3)C=3N=CC=NC=3)=CN=2)C)=C1 XXYGTCZJJLTAGH-UHFFFAOYSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000010206 cystoid macular edema Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N fumaric acid group Chemical group C(\C=C\C(=O)O)(=O)O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- AXXNRMISICMFNS-UHFFFAOYSA-N n-[5-(4-acetylpiperazin-1-yl)pyridin-2-yl]-2-[6-(2-fluoropyridin-4-yl)-5-methylpyridin-3-yl]acetamide Chemical compound C1CN(C(=O)C)CCN1C(C=N1)=CC=C1NC(=O)CC1=CN=C(C=2C=C(F)N=CC=2)C(C)=C1 AXXNRMISICMFNS-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001474 proteinuria Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Claims (19)
1. Spoj, naznačen time, da ima formulu (6):
[image]
ili njegova farmaceutski prihvatljiva sol, gdje: su X1, X2, X3 i X4 odabrani od N i CR7,
jedan od X5, X6, X7 i X8 je N i ostali su CH,
X9 je odabran od N i CH,
Z je odabran od sljedećih: fenil, piranizil, piridinil, piridazinil i piperazinil;
pri čemu je svaki fenil, pirazinil, piridinil, piridazinil ili piperazinil od Z opcijski supstituiran s R6-skupinom;
R1, R2 i R3 su vodik;
m je 1;
R4 je odabran od sljedećih: vodik, halogen, difluorometil, trifluorometil i metil;
R6je odabran od sljedećih: vodik, halogen i -C(O)R10, pri čemu R10 je metil; i
R7 je odabran od sljedećih: vodik, halogen, cijano, metil i trifluorometil.
2. Spoj prema zahtjevu 1, naznačen time, da je taj spoj odabran od sljedećih:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema zahtjevu 1, naznačen time, da taj spoj je 2-(2',3-dimetil-2,4'-bipiridin-5-il)-N-(5-(pirazin-2-il)piridin-2-il)acetamid, ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema zahtjevu 1, naznačen time, da taj spoj je N-(2,3'-bipiridin-6'-il)-2-(2',3-dimetil-2,4'-bipiridin-5-il)acetamid, ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema zahtjevu 1, naznačen time, da taj spoj je N-(5-(4-acetilpiperazin-1-il)piridin-2-il)-2-(2'-fluoro-3-metil-2,4'-bipiridin-5-il)acetamid, ili njegova farmaceutski prihvatljiva sol.
6. Spoj, naznačen time, da ima formulu (5):
[image]
ili njegova farmaceutski prihvatljiva sol, gdje:
A1 je piperazinil supstituiran s -C(O)CH3,
[image]
ili je odabran od sljedećih:
[image]
prsten E je fenil ili jedan od X1, X2, X3 i X4 je N i ostali su CR7;
jedan od X5, X6, X7 i X8 je N i ostali su CR11;
Z je 6-člani heterocikl ili je 6-člani heteroaril, od kojih svaki sadrži 1-2 dušikovih heteroatoma i svaki od njih je opcijski supstituiran s 1-2 R6-skupine;
R1, R2 i R3 su H;
R4i R6su neovisno vodik, cijano, C1-6alkoksi, -S(O)2R10, -C(O)NR8R9, -1-C(O)R10, -1-C(O)OR10, C1-6alkil opcijski supstituiran sa sljedećima: halogen, C2-6alkenil ili C2-6alkinil;
R5je H ili C1-6alkil;
L je veza ili (CR2)1-4 gdje R je H ili C1-6alkil;
W je C3-7cikloalkil;
R7i R11 su neovisno H, halogen, cijano, C1-6alkoksi, -S(O)2R10 ili opcijski halogenirani C1-6alkil;
R8 i R9 su neovisno H, -L-W ili C1-6alkil, C2-6alkenil ili C2-6alkinil, od kojih svaki može biti opcijski supstituiran sa sljedećima: halogen, amino, hidroksil, alkoksi ili cijano;
ili R8 i R9 zajedno s atomima na koje su priključeni, mogu tvoriti prsten;
R10je C1-6alkil ili -L-W; i
m, n i p su neovisno 0-2.
7. Spoj prema zahtjevu 6 ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da A1 je piperazinil supstituiran s -C(O)CH3,
[image]
ili je odabran od sljedećih:
[image]
i m je 0-1.
8. Spoj prema bilo kojem od zahtjeva 6 do 7, naznačen time, da je taj spoj odabran od sljedećih:
[image]
[image]
[image]
[image]
[image]
[image]
ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema bilo kojem od zahtjeva 6 do 7, naznačen time, da je Z odabran od sljedećih: pirazinil, piridinil, piridazinil i piperazinil; pri čemu je svaki pirazinil, piridinil, piridazinil ili piperazinil od Z opcijski supstituiran s R6-skupinom.
10. Spoj prema bilo kojem od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da spomenuta farmaceutski prihvatljiva sol je sol fumarne kiseline toga spoja.
11. Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 9 ili njegovu farmaceutski prihvatljivu sol te fiziološki prihvatljiv nosač.
12. Uporaba spoja prema bilo kojem od zahtjeva 1 do 10, ili njegove farmaceutski prihvatljive soli, ili farmaceutskog sastava prema zahtjevu 11, naznačena time, da je za proizvodnju lijeka za liječenje poremećaja posredovanog putem WNT.
13. Spoj prema bilo kojem od zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u postupku liječenja poremećaja posredovanog putem WNT.
14. Uporaba prema zahtjevu 12, ili spoj ili njegova farmaceutski prihvatljiva sol za uporabu u postupku liječenja, prema zahtjevu 13, naznačen(a) time, da je poremećaj posredovan putem WNT, sljedeći: keloidi, fibroze, proteinurija, odbacivanje bubrežnih usadaka, osteoartritis, Parkinsonova bolest, cistoidni makularni edem, retinopatija, makularna degeneracija ili stanični proliferativni poremećaj povezan sa zastranjivanjem signalnog djelovanja WNT.
15. Uporaba ili spoj ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku liječenja prema zahtjevu 14, naznačen(a) time, da spomenuti poremećaj je stanični proliferativni poremećaj povezan sa zastranjivanjem signalnog djelovanja WNT, koji je odabran iz skupine koju čine kolorektalni rak, kolorektalni karcinom, rak dojke, karcinom rožnatih stanica glave i vrata, ezofagealni rak, ezofagealni karcinom rožnatih stanica, rak ne-malih stanica pluća, rak želudca, rak gušterače, leukemija, limfom, neuroblastom, retinoblastom, sarkom, osteosarkom, hondosarkom, Ewingov sarkom, rabdomiosarkom, tumor mozga, Wilmov tumor, karcinom bazalnih stanica, melanom, rak glave i vrata, cervikalni rak i rak prostate.
16. Uporaba spoja prema bilo kojem od zahtjeva 1 do 10, ili njegove farmaceutski prihvatljive soli ili farmaceutskog sastava prema zahtjevu 11, naznačena time, da je za proizvodnju lijeka za liječenje poremećaja koji se može liječiti inhibicijom signalizacije WNT.
17. Spoj prema bilo kojem od zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u postupku liječenja poremećaja koji se može liječiti inhibicijom signalizacije WNT.
18. Uporaba spoja prema bilo kojem od zahtjeva 1 do 10, ili njegove farmaceutski prihvatljive soli ili farmaceutskog sastava prema zahtjevu 11, naznačena time, da je za proizvodnju lijeka za liječenje poremećaja koji se može liječiti inhibicijom Porcupine-gena.
19. Spoj prema bilo kojem od zahtjeva 1 do 10, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u postupku liječenja poremećaja koji se može liječiti inhibicijom Porcupine-gena.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15659909P | 2009-03-02 | 2009-03-02 | |
US24518709P | 2009-09-23 | 2009-09-23 | |
PCT/US2010/025813 WO2010101849A1 (en) | 2009-03-02 | 2010-03-01 | N- (hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as wnt signaling modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140156T1 true HRP20140156T1 (hr) | 2014-03-14 |
Family
ID=42112245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140156AT HRP20140156T1 (hr) | 2009-03-02 | 2014-02-18 | Acetamidi supstituirani s n-(hetero)aril,2-(hetero)aril, koji se upotrebljavaju kao wnt-signalni modulatori |
Country Status (41)
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
CN102361874A (zh) | 2009-03-23 | 2012-02-22 | 格兰马克药品股份有限公司 | 作为trpa1调节剂的呋喃并嘧啶二酮衍生物 |
NZ601924A (en) * | 2010-03-10 | 2014-10-31 | Astrazeneca Ab | 4-phenyl pyridine analogues as protein kinase inhibitors |
UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
DK3311666T3 (da) | 2010-08-18 | 2021-06-28 | Biosplice Therapeutics Inc | Diketoner og hydroxyketoner som aktivatorer af catenin-signalvejen |
EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
EP2573085A1 (en) | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range |
US20150125857A1 (en) * | 2012-02-28 | 2015-05-07 | Novartis Ag | CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |
WO2013138753A1 (en) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
US9234176B2 (en) * | 2012-11-13 | 2016-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chemically defined production of cardiomyocytes from pluripotent stem cells |
KR101418168B1 (ko) * | 2012-11-21 | 2014-07-09 | 부경대학교 산학협력단 | 신규 테트라하이드로피리디놀 유도체 화합물 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약제학적 조성물 |
DK2968249T3 (en) | 2013-02-22 | 2019-03-04 | Samumed Llc | GAMMA DIKETONS AS WNT / BETA-CATENIN SIGNAL ROAD ACTIVATORS |
CN103113353B (zh) * | 2013-03-13 | 2014-09-10 | 中国科学院昆明植物研究所 | 三氮唑类化合物,其药物组合物和其制备方法与应用 |
TWI582239B (zh) | 2013-03-11 | 2017-05-11 | 諾華公司 | 與wnt抑制劑相關之標記 |
US9713612B2 (en) | 2013-03-12 | 2017-07-25 | Curegenix, Inc. | Compounds for treatment of cancer |
GB2513403A (en) * | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
GB201309333D0 (en) * | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
CN105518005B (zh) | 2013-07-02 | 2018-07-20 | 百时美施贵宝公司 | 作为rock抑制剂的三环吡啶-甲酰胺衍生物 |
AR096788A1 (es) | 2013-07-02 | 2016-02-03 | Bristol Myers Squibb Co | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock |
EP3039021A1 (en) | 2013-08-30 | 2016-07-06 | Ambit Biosciences Corporation | Biaryl acetamide compounds and methods of use thereof |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR20220126813A (ko) | 2014-03-14 | 2022-09-16 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
WO2015145388A2 (en) | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
KR20160147800A (ko) * | 2014-05-06 | 2016-12-23 | 에프. 호프만-라 로슈 아게 | 다능성 줄기세포의 심근세포로의 분화 방법 |
BR112017003959B1 (pt) | 2014-08-20 | 2022-08-02 | Samumed, Llc | Uso de um composto de fórmula i ou um sal dermatologicamente aceitável do mesmo |
US9765299B2 (en) | 2014-09-10 | 2017-09-19 | Wisconsin Alumni Research Foundation | Chemically defined albumin-free conditions for cardiomyocyte differentiation of human pluripotent stem cells |
EP3659621A1 (en) | 2014-09-13 | 2020-06-03 | Novartis AG | Combination therapies for cancer |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
PT3204381T (pt) | 2014-10-08 | 2022-07-18 | Redx Pharma Plc | Derivados de n-piridinil acetamida como inibidores da via de sinalização wnt |
WO2016055786A1 (en) * | 2014-10-08 | 2016-04-14 | Redx Pharma Plc | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway |
US9988452B2 (en) | 2014-10-14 | 2018-06-05 | Novartis Ag | Antibody molecules to PD-L1 and uses thereof |
WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
CA2976972A1 (en) * | 2015-02-20 | 2016-08-25 | Bayer Pharma Aktiengesellschaft | 1,3,4-thiadiazol-2-yl-benzamide derivatives as inhibitorsof the wnt signalling pathway |
JP6692826B2 (ja) | 2015-03-10 | 2020-05-13 | アドゥロ バイオテック,インク. | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法 |
CN104876912B (zh) * | 2015-04-08 | 2017-07-21 | 苏州云轩医药科技有限公司 | Wnt信号通路抑制剂及其应用 |
EP3302479A4 (en) * | 2015-05-26 | 2019-01-09 | Curegenix Corporation | TUMOR BIOMARKERS AND USE THEREOF |
KR20180011117A (ko) | 2015-05-31 | 2018-01-31 | 큐어제닉스 코포레이션 | 면역 요법용 복합 조성물 |
RU2729936C2 (ru) | 2015-06-16 | 2020-08-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противораковое средство |
SG11201709593VA (en) | 2015-06-23 | 2017-12-28 | Eisai R&D Man Co Ltd | CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND |
US10624949B1 (en) | 2015-07-27 | 2020-04-21 | National Technology & Engineering Solutions Of Sandia, Llc | Methods for treating diseases related to the wnt pathway |
PL3317301T3 (pl) | 2015-07-29 | 2021-11-15 | Novartis Ag | Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
PT3344758T (pt) | 2015-09-01 | 2021-10-28 | Ncardia B V | Um método in vitro para diferenciação de uma população de células estaminais pluripotentes humanas numa população de células de cardiomiócitos |
CN107759584B (zh) * | 2016-08-16 | 2021-06-01 | 苏州云轩医药科技有限公司 | 一种具有Wnt信号通路抑制活性的氨基五元杂环化合物及其应用 |
RS63125B1 (sr) | 2015-11-03 | 2022-05-31 | Janssen Biotech Inc | Antitela koja se specifično vezuju za pd-1 i njihova upotreba |
CN106749259B (zh) * | 2015-11-19 | 2019-02-01 | 华东师范大学 | 一种环戊基嘧啶并吡咯类化合物的合成方法 |
US10821104B2 (en) * | 2015-12-07 | 2020-11-03 | Suzhou Sinovent Pharmaceuticals Co., Ltd. | Five-membered heterocyclic amides WNT pathway inhibitor |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
AR108325A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
CA3028586A1 (en) | 2016-06-22 | 2017-12-28 | Novartis Ag | Wnt inhibitors for use in the treatment of fibrosis |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
JP2020506159A (ja) * | 2017-02-14 | 2020-02-27 | ノバルティス アーゲー | 組み合わせでのWnt阻害剤および抗PD−1抗体分子の投与スケジュール |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
CN107441045B (zh) | 2017-07-21 | 2018-10-19 | 广州源生医药科技有限公司 | 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法 |
CN108586452A (zh) * | 2018-01-12 | 2018-09-28 | 重庆市碚圣医药科技股份有限公司 | 一种帕博西尼中间体的合成方法 |
WO2019157085A2 (en) * | 2018-02-06 | 2019-08-15 | Vanderbilt University | INHIBITION OF WNT/β-CATENIN SIGNALING IN THE TREATMENT OF OSTEOARTHRITIS |
KR20200135463A (ko) * | 2018-03-23 | 2020-12-02 | 스텝 파마 에스.에이.에스. | Ctps1 억제제로서 아미노피리미딘 유도체 |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
WO2020014652A1 (en) * | 2018-07-13 | 2020-01-16 | New York University | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same |
US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
CN111349093B (zh) * | 2018-12-21 | 2021-07-02 | 汇瀚医疗科技有限公司 | 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用 |
WO2020125759A1 (zh) * | 2018-12-21 | 2020-06-25 | 汇瀚医疗科技有限公司 | 作为wnt信号通路抑制剂的化合物及其医学应用 |
US11369609B2 (en) * | 2019-05-02 | 2022-06-28 | Yale University | Small molecule Wnt inhibitor as treatment for dyslipidemia |
CN114072408B (zh) * | 2019-07-08 | 2023-05-12 | 南京明德新药研发有限公司 | 作为porcupine抑制剂的化合物及其应用 |
US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
JP7461605B2 (ja) * | 2020-02-20 | 2024-04-04 | 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 | キノリン系化合物 |
IT202000019897A1 (it) * | 2020-08-10 | 2022-02-10 | Olon Spa | Procedimento per la preparazione di un intermedio chiave del siponimod |
KR20230093251A (ko) | 2020-09-10 | 2023-06-27 | 프리시릭스 엔.브이. | Fap에 대한 항체 단편 |
CN112472701B (zh) * | 2020-12-04 | 2021-08-31 | 复旦大学附属中山医院 | Wnt抑制剂Wnt-C59在制备治疗SCN5A突变致扩张型心肌病的药物中的应用 |
WO2023072263A1 (zh) * | 2021-10-29 | 2023-05-04 | 南京明德新药研发有限公司 | 5-取代的吡啶-2(1h)-酮类化合物及其应用 |
KR102416464B1 (ko) * | 2021-11-24 | 2022-07-05 | 중앙대학교 산학협력단 | Lgk974를 포함하는 염증성 신장질환 예방 또는 치료용 조성물 |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
CN116514779A (zh) * | 2022-05-06 | 2023-08-01 | 中南大学 | 2,4-二取代-5-氟嘧啶衍生物及其制备方法和应用 |
WO2024009232A1 (en) * | 2022-07-05 | 2024-01-11 | Aurigene Oncology Limited | Substituted n-(pyridin-2-yl)acetamide derivatives as cdk12/13 inhibitors |
CN115784839A (zh) * | 2022-11-11 | 2023-03-14 | 浙江工业大学 | 一种4-环己基-3-(三氟甲基)苯甲醇的制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
TW225528B (hr) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
KR100423899B1 (ko) * | 2000-05-10 | 2004-03-24 | 주식회사 엘지생명과학 | 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸 |
JP2002053566A (ja) * | 2000-08-11 | 2002-02-19 | Japan Tobacco Inc | チアゾール化合物及びその医薬用途 |
US20030225081A1 (en) | 2000-09-18 | 2003-12-04 | Satoshi Nagato | Pyridazinones and triazinones and medicinal use thereof |
TWI335221B (en) * | 2001-09-27 | 2011-01-01 | Alcon Inc | Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma |
US6762185B1 (en) * | 2002-03-01 | 2004-07-13 | Choongwae Pharma Corporation | Compounds useful for treatment of cancer, compositions containing the same, and methods of their use |
FR2847253B1 (fr) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
US8030336B2 (en) * | 2002-12-13 | 2011-10-04 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
ES2320758T3 (es) | 2002-12-18 | 2009-05-28 | Mallinckrodt Inc. | Sintesis de heteroaril acetamidas. |
DE10306250A1 (de) | 2003-02-14 | 2004-09-09 | Aventis Pharma Deutschland Gmbh | Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US7652043B2 (en) * | 2004-09-29 | 2010-01-26 | The Johns Hopkins University | WNT pathway antagonists |
GB0507575D0 (en) * | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
WO2006116503A2 (en) | 2005-04-26 | 2006-11-02 | Irm Llc | Methods and compositions for modulating wnt signaling pathway |
MX2009004716A (es) | 2006-11-03 | 2009-07-17 | Irm Llc | Compuestos y composiciones en la forma de inhibidores de quinasa de proteina. |
EP1932830A1 (en) * | 2006-12-11 | 2008-06-18 | The Genetics Company, Inc. | Sulfonamides and their use as a medicament |
JP2010526078A (ja) * | 2007-04-30 | 2010-07-29 | ジェネンテック, インコーポレイテッド | Wntシグナル伝達のピラゾールインヒビター |
EP2003119A1 (de) | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Acetamide als Modulatoren des EP2-Rezeptors |
CN101896461A (zh) * | 2007-12-13 | 2010-11-24 | 安姆根有限公司 | γ分泌酶调节剂 |
EP2393806B1 (en) * | 2009-02-06 | 2017-10-25 | Elan Pharmaceuticals, Inc. | Inhibitors of jun n-terminal kinase |
UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
UY33469A (es) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
-
2010
- 2010-01-03 UA UAA201111538A patent/UA103918C2/uk unknown
- 2010-02-28 JO JO201073A patent/JO2933B1/en active
- 2010-03-01 MA MA34217A patent/MA33157B1/fr unknown
- 2010-03-01 PL PL10708670T patent/PL2403832T3/pl unknown
- 2010-03-01 EP EP10708670.4A patent/EP2403832B1/en active Active
- 2010-03-01 PE PE2011001579A patent/PE20120650A1/es active IP Right Grant
- 2010-03-01 NZ NZ595339A patent/NZ595339A/xx unknown
- 2010-03-01 AR ARP100100593A patent/AR076067A1/es active IP Right Grant
- 2010-03-01 AU AU2010221493A patent/AU2010221493C1/en active Active
- 2010-03-01 CA CA2753552A patent/CA2753552C/en active Active
- 2010-03-01 GE GEAP201012397A patent/GEP20146033B/en unknown
- 2010-03-01 CN CN201080010081.3A patent/CN102369187B/zh active Active
- 2010-03-01 PT PT107086704T patent/PT2403832E/pt unknown
- 2010-03-01 WO PCT/US2010/025813 patent/WO2010101849A1/en active Application Filing
- 2010-03-01 ES ES13166120.9T patent/ES2543320T3/es active Active
- 2010-03-01 CR CR20190039A patent/CR20190039A/es unknown
- 2010-03-01 DK DK10708670.4T patent/DK2403832T3/da active
- 2010-03-01 EP EP20130166120 patent/EP2623493B1/en active Active
- 2010-03-01 BR BRPI1009235A patent/BRPI1009235B8/pt active IP Right Grant
- 2010-03-01 EA EA201101244A patent/EA021225B1/ru not_active IP Right Cessation
- 2010-03-01 SI SI201030517T patent/SI2403832T1/sl unknown
- 2010-03-01 JP JP2011553013A patent/JP5490153B2/ja active Active
- 2010-03-01 MY MYPI2011004048 patent/MY150583A/en unknown
- 2010-03-01 ES ES10708670.4T patent/ES2445526T3/es active Active
- 2010-03-01 MX MX2011009246A patent/MX2011009246A/es active IP Right Grant
- 2010-03-01 SG SG2011054806A patent/SG173467A1/en unknown
- 2010-03-01 US US13/132,294 patent/US8546396B2/en active Active
- 2010-03-01 CN CN201210225401.8A patent/CN102731379B/zh active Active
- 2010-03-01 GE GEAP201012768A patent/GEP20146082B/en unknown
- 2010-03-01 NZ NZ603137A patent/NZ603137A/xx unknown
- 2010-03-01 KR KR1020117023086A patent/KR101359873B1/ko active IP Right Grant
- 2010-03-02 UY UY0001032469A patent/UY32469A/es active IP Right Grant
- 2010-03-02 TW TW099106008A patent/TWI429644B/zh active
- 2010-03-02 TW TW102103789A patent/TW201329070A/zh unknown
-
2011
- 2011-08-03 TN TN2011000378A patent/TN2011000378A1/fr unknown
- 2011-08-08 IL IL214516A patent/IL214516A/en active IP Right Grant
- 2011-08-24 CU CU2011000165A patent/CU24050B1/es active IP Right Grant
- 2011-08-30 CL CL2011002116A patent/CL2011002116A1/es unknown
- 2011-08-31 DO DO2011000273A patent/DOP2011000273A/es unknown
- 2011-09-01 HN HN2011002346A patent/HN2011002346A/es unknown
- 2011-09-01 NI NI201100165A patent/NI201100165A/es unknown
- 2011-09-12 CO CO11117875A patent/CO6450669A2/es active IP Right Grant
- 2011-09-15 ZA ZA2011/06750A patent/ZA201106750B/en unknown
- 2011-09-29 EC EC2011011359A patent/ECSP11011359A/es unknown
- 2011-10-03 CR CR20110520A patent/CR20110520A/es unknown
-
2012
- 2012-02-01 HK HK12100917.6A patent/HK1160464A1/xx unknown
-
2013
- 2013-07-22 US US13/948,038 patent/US9238646B2/en active Active
-
2014
- 2014-02-18 HR HRP20140156AT patent/HRP20140156T1/hr unknown
- 2014-02-25 JP JP2014034483A patent/JP2014129381A/ja active Pending
- 2014-03-19 SM SM201400032T patent/SMT201400032B/xx unknown
-
2015
- 2015-12-08 US US14/962,432 patent/US20160082014A1/en not_active Abandoned
-
2017
- 2017-09-08 US US15/699,112 patent/US10251893B2/en active Active
-
2021
- 2021-03-12 UY UY0001039128A patent/UY39128A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140156T1 (hr) | Acetamidi supstituirani s n-(hetero)aril,2-(hetero)aril, koji se upotrebljavaju kao wnt-signalni modulatori | |
JP2013533879A5 (hr) | ||
HRP20180916T1 (hr) | Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba | |
HRP20201469T1 (hr) | Derivati tetrahidroizokinolina | |
JP2019517487A5 (hr) | ||
HRP20220864T1 (hr) | Derivati n-piridinil acetamida kao inhibitori signalnog puta wnt | |
JP2017530185A5 (hr) | ||
HRP20170352T1 (hr) | Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori | |
HRP20151410T1 (hr) | Derivati pikolinamida kao inhibitori kinaze | |
JP2014506599A5 (hr) | ||
HRP20201430T1 (hr) | Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
HRP20141094T1 (hr) | 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze | |
JP2020504747A5 (hr) | ||
NZ734744A (en) | Aryl-or heteroaryl-substituted benzene compounds | |
JP2016522246A5 (hr) | ||
HRP20170103T1 (hr) | Triazolopiridazini kao modulatori tirozin kinaze | |
JP2011520941A5 (hr) | ||
JP2016525078A5 (hr) | ||
HRP20130861T1 (hr) | 1 h-benzimidazol-4-karboksamidi supstituirani s kvartarnim ugljikom na 2-položaju kao inhibitori parp-a za uporabu u lijeäśenju karcinoma | |
SI2970216T1 (en) | Biaryl-amide compounds as kinase inhibitors | |
JP2017532360A5 (hr) | ||
JP2012507566A5 (hr) | ||
HRP20121023T1 (hr) | Inhibitori za iap | |
HRP20201400T1 (hr) | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa | |
SI3125888T1 (en) | 2,4-TIAZOLIDINDION DERIVATIVES FOR TREATMENT OF CENTRAL STYLE SYSTEM DISEASE |